Article Text

PDF
SAT0103 Lithe: Tocilizumab (TCZ) Inhibits Radiographic Progression and Improves Physical Function in Patients (PTS) With Rheumatoid Arthritis (RA) at 5 Years With Maintenance of Clinical Efficacy Over Time
  1. J. Kremer1,
  2. A.-M. Halland2,
  3. M. Brzosko3,
  4. R. Burgos-Vargas4,
  5. C. Mela5,
  6. E. Vernon5,
  7. R. Fleischmann6
  1. 1Albany Med Coll, Albany, United States
  2. 2Panorama Med Ctr, Cape Town, South Africa
  3. 3Pomeranian Med U, Szczecin, Poland
  4. 4Hosp General de México and U Nacional Autónoma de México, Mexico City, Mexico
  5. 5Roche, Welwyn, United Kingdom
  6. 6Metroplex Clin Res Ctr, Dallas, United States

Abstract

Background LITHE was a 2-y, randomised, double-blind, placebo-controlled study of TCZ in pts with moderate to severe RA who were inadequate responders to methotrexate (MTX) with an additional 3 y of open-label extension.

Objectives To report radiographic, efficacy and safety data in RA pts treated with TCZ in LITHE at 5 y of follow up.

Methods In LITHE, 1190 pts were randomised (1:1:1) to receive TCZ (4 mg/kg [TCZ4] or 8 mg/kg [TCZ8]) or placebo every 4 wks + MTX (10-25 mg/wk). Mean duration of RA at study entry was 8.96 to 9.43 y in the 3 arms. Pts could receive rescue with TCZ from wk 16; after wk 52, pts could switch to open-label TCZ8. Radiographs were analysed by Genant-modified Total Sharp Score (GmTSS) at baseline (BL) and at wks 52, 104, 152, 200 and 260 by original randomised group. Pts with at least BL, wk 104 and post-wk 104 radiographs were included in the analysis; linear extrapolation was used to impute any additional missing time points. Signs and symptoms and safety data were pooled for all pts who received ≥1 dose of TCZ (All TCZ) with data presented from the first dose of TCZ. LOCF was used for missing tender and swollen joint counts; no imputation was used for missing HAQ-DI score, CRP, ESR and VAS assessments. The proportions of pts who maintained an ACR20/50/70, DAS28-ESR, EULAR or HAQ-DI response consecutively for ≥24 wks at any time point during the study were summarised (Table).

Results 1149 pts received ≥1 dose of TCZ with 4379.6 pt-y (PY) of exposure, and 34% received 5 y of treatment (All TCZ). Mean duration in the All TCZ population was 3.81 y with half the pts participating for ≥4.69 y. Radiographic data were assessed in 803 pts: 545 initially assigned to TCZ and 258 initially assigned to placebo. The mean change in GmTSS over 5 y showed a 56% greater inhibition of joint damage in pts randomised to TCZ vs those initially randomised to placebo, with greatest APR in y 1 (Table). 53% of TCZ pts had no progression (GmTSS≤0) during the 5 y vs 35% of placebo pts (placebo pts might have switched to TCZ as early as wk 16). Clinical benefit was maintained, as measured by maintenance of ACR response, DAS28-ESR remission and EULAR good/moderate response (Table). Overall rates/100PY of serious adverse events and serious infections were 11.67 and 3.42, respectively. The safety profile at 5 y was similar to that observed at 2 y.1

Conclusions During long-term treatment, TCZ + MTX continued to inhibit radiographic progression. Improvements in signs and symptoms and in physical function were maintained with continued TCZ treatment. The safety profile of TCZ at 5 y was similar to that previously observed.1

References

  1. Ann Rheum Dis 2010;69(suppl 3):387

Disclosure of Interest J. Kremer Grant/research support from: Genentech, Consultant for: Genentech, A.-M. Halland: None Declared, M. Brzosko: None Declared, R. Burgos-Vargas Grant/research support from: Abbott, Consultant for: Abbott, BMS, Janssen, Pfizer, Roche, Speakers bureau: Abbott, BMS, Janssen, Pfizer, Roche, C. Mela Employee of: Roche, E. Vernon Employee of: Roche, R. Fleischmann Grant/research support from: Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi Aventis, Lilly, MSD, Pfizer, Regeneron, Consultant for: Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi Aventis, Lilly, MSD, Pfizer, Regeneron

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.